Pharmaceutical
Healthcare
Health

Merck

22,626

$77.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.62 (+0.81%) Today
-$0.09 (-0.12%) As of 6:02 AM EDT after-hours

Why Robinhood?

You can buy or sell Merck and other stocks, options, ETFs, and crypto commission-free!

About MRK

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Read More The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

CEO
Kenneth C. Frazier
Employees
71,000
Headquarters
Kenilworth, New Jersey
Founded
1891
Market Cap
195.24B
Price-Earnings Ratio
19.41
Dividend Yield
3.02
Average Volume
8.66M
High Today
$78.58
Low Today
$76.73
Open Price
$76.97
Volume
7.74M
52 Week High
$92.64
52 Week Low
$65.25

Collections

Pharmaceutical
Healthcare
Health
Medical
Manufacturing
Health And Wellness
Technology
Therapy

MRK News

BenzingaJul 9

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai Co., Ltd. Public Relations: +81-(0)3-3817-5120 Merck & Co., Inc., Kenilworth, N.J., U.S.A. Media Relations Pamela Eisele: (267) 305-3558 Michael Close: (2
0
ReutersJul 8

BRIEF-Zymeworks & Merck Sign New License Agreement

July 8 (Reuters) - Merck & Co Inc: * ZYMEWORKS - CO & MERCK SIGNED NEW LICENSE AGREEMENT * ZYMEWORKS - AGREEMENT GRANTS MERCK RIGHT TO DEVELOP ADDITIONAL MULT
0
MarketWatchJul 8

Merck, Eisai to put experimental cancer combination in new clinical trial

Shares of Merck & Co. Inc. MRK, -1.08% gained 0.1% in premarket trading on Wednesday after it received a complete response letter from the Food and Drug Adminis
0

MRK Earnings

$0.00
$0.50
$1.01
$1.51
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Available Jul 31, Pre-Market

You May Also Like

SNUG
EH
ROKT
IYC
TELNY
ERSX
WUBA
CCH+
ARKF
IBMI

More MRK News

ReutersJul 8

AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London, April 28, 2014. REUTERS/Stefan Wermuth/File Photo (Reuters) - Astra
0
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy MRK

Market Price$77.26
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell Merck stock and options commission-free.
LearnBlogCareersHelpLog InSign Up